+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology ({Type-Cleavable, Non-cleavable}), By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 135 Pages
  • May 2023
  • Region: Global
  • Grand View Research
  • ID: 5416004
Description Jump to:
The global antibody drug conjugates market size is expected to reach USD 22.35 billion by 2030, registering a CAGR of 11.2% over the forecast period. The presence of strong pipeline products and strategic initiatives undertaken by the key players are expected to drive the market growth during the forecast period.

Key players such as ADC Therapeutics, Seagen. Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., AstraZeneca, Daiichi Sankyo, and others are collaborating to develop and commercialize products. For instance, in February 2022, Mersana Therapeutics, partnered with Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson Inc., for the research and development of novel ADCs to treat various cancers. Under this agreement, Janssen will pay Mersana Therapeutics USD 40.0 million upfront and potentially more than USD 1.0 billion in milestone-based payments for the development of new ADCs.

Extensive research and rising funding for the development of novel antibody-drug conjugates by pharmaceutical companies is projected to drive market growth. For instance, in April 2021, Adcendo and Adcentrx, two new startups raised funding of around USD 112.0 million for the development of ADCs with their new approach to the treatment of cancer. Adcendo raised USD 51.0 million for the development of new ADCs that target endocytic receptors, which play the role of the drug delivery body. Adcentrx raised USD 50.0 million for its ADC research programs.

Additionally, in March 2022, ImmunoGen, Inc. announced the submission of biological license application (BLA) to the U. S. FDA for mirvetuximab soravtansine used as monotherapy in patients with ovarian cancer. It comprises alpha-binding antibody, cleavable linker, and the maytansinoid DM4 as payload to kill the targeted cancer cells.

Stringent reimbursement policies for ADCs may restrain the market growth due to the high cost associated with the treatment of ADCs as compared to the alternative conventional treatments such as monoclonal antibodies therapy & chemotherapy. This higher cost of treatment is expected to impede reimbursement coverage. For instance, in February 2020, National Centre for Pharmaco economics, Ireland, gave a negative review for Roche’s Kadcyla (trastuzumab emtansine) for reimbursement consideration due to its low cost-effectiveness.

The rising geriatric population coupled with the increasing prevalence of the diseases such as multiple myeloma (MM) is expected to drive demand for ADCs, thereby driving the market growth during the forecast period. Multiple myeloma (MM) is a disease of the aging population, and nearly 30,000 new cases of MM were diagnosed in 2021. The median age of diagnosed patients with multiple myeloma is 70 years. Thus, the introduction of new ADCs for the treatment of multiple myeloma is expected to boost market growth. For instance, in August 2020, the FDA approved BLENREP by GlaxoSmithKline as a monotherapy to treat relapsed or refractory multiple myeloma. Blenrep was the first anti-BCMA therapy approved for the treatment of multiple myeloma.

Antibody Drug Conjugates Market Report Highlights

  • Breast cancer dominated the market for the largest revenue share of 50.61% in 2022, owing to the high prevalence of breast cancer and the availability of multiple ADC products for treating the breast cancer
  • Cleavable linker segment accounted for largest revenue share of 65.20% in 2022 due to the rising adoption of cleavable linker technology in commercial ADC products and the advantages associated with the use of cleavable linkers over other linker technology
  • Based on linker Technology Type, others segment dominated the market due to presence of a large number of highly effective linkers in market such as SMCC, SPP, MCC, maleimide tetrapeptide, CL2A, and MC (Maleimidocaproyl) used to deliver payloads to their target sites.
  • North America dominated the market in terms of revenue share of 53.29% in 2022 due to the presence of key pharmaceutical companies such as Pfizer, Inc, Gilead Life Sciences, Inc., and Seagen, Inc. and their strategic initiatives for the development of new ADCs


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology And Scope
1.1 Market Segmentation And Scope
1.1.1 Segment Definitions
1.1.1.1 Application Segment
1.1.1.2 Technology Segment
1.2 Regional Scope
1.3 Estimates And Forecast Timeline
1.4 Objectives
1.4.1 Objective - 1
1.4.2 Objective - 2
1.4.3 Objective - 3
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 Internal Database
1.6.3 Secondary Sources
1.6.4 Primary Research
1.7 Information Or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List Of Secondary Sources
1.11 List Of Abbreviations
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Technology And Application Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation And Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends And Outlook
3.4. Market Dynamics
3.4.1. Presence Of Strong Product Pipeline
3.4.2. Growing Geriatric Population Base
3.4.3. Increasing Incidence And Prevalence Of Cancer
3.5. Market Restraint Analysis
3.5.1. High Manufacturing Cost And Downstream Processing Challenges For Adcs
3.5.2. Analytical Challenges For Adc
3.5.3. Stringent Reimbursement Policies For Adcs
3.6. Business Environment Analysis
3.6.1. Swot Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2. Porter’s Five Forces Analysis
3.6.3. Covid-19 Impact Analysis
3.7. Qualitative Analysis For Adc Development Platforms
3.7.1. Creative Biolabs
3.7.2. Mersana Therapeutics
3.7.3. Heidelberg Pharma
3.7.4. Synaffix Bv
3.7.5. Nbe Therapeutics
3.7.6. Veraxa
3.7.7. Tubulis Gmbh
3.7.8. Byondis Platform
3.7.9. Immunogen, Inc.
3.7.10. Remegen
3.7.11. Wuxi Biologics
3.7.12. Merck Kgaa
3.7.13. Ambrx
Chapter 4. Antibody Drug Conjugates Market: Segment Analysis By Application, 2018 - 2030 (USD Million)
4.1. Antibody Drug Conjugates Market: Application Movement Analysis
4.2. Blood Cancer
4.2.1. Blood Cancer Market, 2018 - 2030 (USD Million)
4.2.2. Leukemia
4.2.2.1. Leukemia Market, 2018 - 2030 (USD Million)
4.2.3. Multiple Myeloma
4.2.3.1. Multiple Myeloma Market, 2018 - 2030 (USD Million)
4.2.4. Lymphoma
4.2.4.1. Lymphoma Market, 2018 - 2030 (USD Million)
4.3. Breast Cancer
4.4. Urothelial/Bladder Cancer
4.4.1. Urothelial/Bladder Cancer Market, 2018 - 2030 (USD Million)
4.5. Others
4.5.1. Others Market, 2018 - 2030 (USD Million)
Chapter 5. Antibody Drug Conjugates Market: Segment Analysis By Technology, 2018 - 2030 (USD Million)
5.1. Antibody Drug Conjugates Market: Technology Movement Analysis
5.2. By Type
5.2.1. Cleavable Linker
5.2.1.1. Cleavable Linker Market, 2018 - 2030 (USD Million)
5.2.2. Non-Cleavable Linker
5.2.2.1. Non-Cleavable Linker Market, 2018 - 2030 (USD Million)
5.2.3. Linkerless
5.2.3.1. Linkerless Market, 2018 - 2030 (USD Million)
5.3. By Linker Technology
5.3.1. Vc (Valine-Citrulline)
5.3.1.1. Vc Market, 2018 - 2030 (USD Million)
5.3.2. Sulfo-Spdb
5.3.2.1. Sulfo-Spdb Market, 2018 - 2030 (USD Million)
5.3.3. Va (Valine Alanine)
5.3.3.1. Va (Valine Alanine) Market, 2018 - 2030 (USD Million)
5.3.4. Hydrazone
5.3.4.1. Hydrazone Market, 2018 - 2030 (USD Million)
5.3.5. Others
5.3.5.1. Others Market, 2018 - 2030 (USD Million)
5.4. By Payload Technology
5.4.1. Mmae
5.4.1.1. Mmae Market, 2018 - 2030 (USD Million)
5.4.2. Mmaf
5.4.2.1. Mmaf Market, 2018 - 2030 (USD Million)
5.4.3. Dm4
5.4.3.1. Dm4 Market, 2018 - 2030 (USD Million)
5.4.4. Camptothecin
5.4.4.1. Camptothecin Market, 2018 - 2030 (USD Million)
5.4.5. Others
5.4.5.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. Antibody Drug Conjugates Market: Regional Analysis, 2018 - 2030 (USD Million)
6.1. Antibody Drug Conjugates Market Share By Region, 2022 & 2030
6.2. North America
6.2.1. Swot Analysis
6.2.2. North America Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
6.2.3. U.S.
6.2.3.1. Key Country Dynamics
6.2.3.2. Target Disease Prevalence
6.2.3.3. Competitive Scenario
6.2.3.4. Regulatory Framework
6.2.3.5. Reimbursement Scenario
6.2.3.6. U.S. Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
6.2.4. Canada
6.2.4.1. Key Country Dynamics
6.2.4.2. Target Disease Prevalence
6.2.4.3. Competitive Scenario
6.2.4.4. Regulatory Framework
6.2.4.5. Reimbursement Scenario
6.2.4.6. Canada Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
6.3. Europe
6.3.1. Swot Analysis
6.3.2. Europe Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
6.3.3. Germany
6.3.3.1. Key Country Dynamics
6.3.3.2. Target Disease Prevalence
6.3.3.3. Competitive Scenario
6.3.3.4. Regulatory Framework
6.3.3.5. Reimbursement Scenario
6.3.3.6. Germany Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
6.3.4. Uk
6.3.4.1. Key Country Dynamics
6.3.4.2. Target Disease Prevalence
6.3.4.3. Competitive Scenario
6.3.4.4. Regulatory Framework
6.3.4.5. Reimbursement Scenario
6.3.4.6. Uk Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
6.3.5. France
6.3.5.1. Key Country Dynamics
6.3.5.2. Target Disease Prevalence
6.3.5.3. Competitive Scenario
6.3.5.4. Regulatory Framework
6.3.5.5. Reimbursement Scenario
6.3.5.6. France Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
6.3.6. Italy
6.3.6.1. Key Country Dynamics
6.3.6.2. Target Disease Prevalence
6.3.6.3. Competitive Scenario
6.3.6.4. Regulatory Framework
6.3.6.5. Reimbursement Scenario
6.3.6.6. Italy Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
6.3.7. Spain
6.3.7.1. Key Country Dynamics
6.3.7.2. Target Disease Prevalence
6.3.7.3. Competitive Scenario
6.3.7.4. Regulatory Framework
6.3.7.5. Reimbursement Scenario
6.3.7.6. Spain Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
6.3.8. Denmark
6.3.8.1. Key Country Dynamics
6.3.8.2. Target Disease Prevalence
6.3.8.3. Competitive Scenario
6.3.8.4. Regulatory Framework
6.3.8.5. Reimbursement Scenario
6.3.8.6. Denmark Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
6.3.9. Sweden
6.3.9.1. Key Country Dynamics
6.3.9.2. Target Disease Prevalence
6.3.9.3. Competitive Scenario
6.3.9.4. Regulatory Framework
6.3.9.5. Reimbursement Scenario
6.3.9.6. Sweden Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
6.3.10. Norway
6.3.10.1. Key Country Dynamics
6.3.10.2. Target Disease Prevalence
6.3.10.3. Competitive Scenario
6.3.10.4. Regulatory Framework
6.3.10.5. Reimbursement Scenario
6.3.10.6. Norway Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
6.4. Asia Pacific
6.4.1. Swot Analysis
6.4.2. Asia Pacific Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
6.4.3. Japan
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Competitive Scenario
6.4.3.4. Regulatory Framework
6.4.3.5. Reimbursement Scenario
6.4.3.6. Japan Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
6.4.4. China
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Competitive Scenario
6.4.4.4. Regulatory Framework
6.4.4.5. Reimbursement Scenario
6.4.4.6. China Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
6.4.5. India
6.4.5.1. Key Country Dynamics
6.4.5.2. Target Disease Prevalence
6.4.5.3. Competitive Scenario
6.4.5.4. Regulatory Framework
6.4.5.5. Reimbursement Scenario
6.4.5.6. India Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
6.4.6. South Korea
6.4.6.1. Key Country Dynamics
6.4.6.2. Target Disease Prevalence
6.4.6.3. Competitive Scenario
6.4.6.4. Regulatory Framework
6.4.6.5. Reimbursement Scenario
6.4.6.6. South Korea Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
6.4.7. Australia
6.4.7.1. Key Country Dynamics
6.4.7.2. Target Disease Prevalence
6.4.7.3. Competitive Scenario
6.4.7.4. Regulatory Framework
6.4.7.5. Reimbursement Scenario
6.4.7.6. Australia Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
6.4.8. Thailand
6.4.8.1. Key Country Dynamics
6.4.8.2. Target Disease Prevalence
6.4.8.3. Competitive Scenario
6.4.8.4. Regulatory Framework
6.4.8.5. Reimbursement Scenario
6.4.8.6. Thailand Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
6.5. Latin America
6.5.1. Swot Analysis
6.5.2. Latin America Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
6.5.3. Brazil
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Competitive Scenario
6.5.3.4. Regulatory Framework
6.5.3.5. Reimbursement Scenario
6.5.3.6. Brazil Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
6.5.4. Mexico
6.5.4.1. Key Country Dynamics
6.5.4.2. Target Disease Prevalence
6.5.4.3. Competitive Scenario
6.5.4.4. Regulatory Framework
6.5.4.5. Reimbursement Scenario
6.5.4.6. Mexico Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
6.5.5. Argentina
6.5.5.1. Key Country Dynamics
6.5.5.2. Target Disease Prevalence
6.5.5.3. Competitive Scenario
6.5.5.4. Regulatory Framework
6.5.5.5. Reimbursement Scenario
6.5.5.6. Argentina Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
6.6. Mea
6.6.1. Swot Analysis
6.6.2. Mea Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
6.6.3. South Africa
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Competitive Scenario
6.6.3.4. Regulatory Framework
6.6.3.5. Reimbursement Scenario
6.6.3.6. South Africa Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
6.6.4. Saudi Arabia
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. Competitive Scenario
6.6.4.4. Regulatory Framework
6.6.4.5. Reimbursement Scenario
6.6.4.6. Saudi Arabia Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
6.6.5. Uae
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Competitive Scenario
6.6.5.4. Regulatory Framework
6.6.5.5. Reimbursement Scenario
6.6.5.6. Uae Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
6.6.6. Kuwait
6.6.6.1. Key Country Dynamics
6.6.6.2. Target Disease Prevalence
6.6.6.3. Competitive Scenario
6.6.6.4. Regulatory Framework
6.6.6.5. Reimbursement Scenario
6.6.6.6. Kuwait Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1 Company Categorization
7.2 Strategy Mapping
7.2.1 New Product Launch
7.2.2 Partnerships
7.2.3 Acquisition
7.2.4 Collaboration
7.2.5 Funding
7.3 Key Company Market Share Analysis, 2022
7.4 Company Profiles
7.4.1 Takeda Pharmaceutical Company Limited
7.4.1.1 Company Overview
7.4.1.2 Financial Performance
7.4.1.3 Product Benchmarking
7.4.1.4 Strategic Initiatives
7.4.2 F.Hoffmann-La Roche Ltd.
7.4.2.1 Company Overview
7.4.2.2 Financial Performance
7.4.2.3 Product Benchmarking
7.4.2.4 Strategic Initiatives
7.4.3 Pfizer, Inc.
7.4.3.1 Company Overview
7.4.3.2 Financial Performance
7.4.3.3 Product Benchmarking
7.4.3.4 Strategic Initiatives
7.4.4 Astrazeneca
7.4.4.1 Company Overview
7.4.4.2 Product Benchmarking
7.4.4.3 Strategic Initiatives
7.4.5 Gilead Sciences, Inc.
7.4.5.1 Company Overview
7.4.5.2 Financial Performance
7.4.5.3 Product Benchmarking
7.4.5.4 Strategic Initiatives
7.4.6 Astellas Pharma Inc.
7.4.6.1 Company Overview
7.4.6.2 Financial Performance
7.4.6.3 Product Benchmarking
7.4.6.4 Strategic Initiatives
7.4.7 Seagen, Inc.
7.4.7.1 Company Overview
7.4.7.2 Financial Performance
7.4.7.3 Product Benchmarking
7.4.7.4 Strategic Initiatives
7.4.8 Daiichi Sankyo Company, Limited
7.4.8.1 Company Overview
7.4.8.2 Financial Performance
7.4.8.3 Product Benchmarking
7.4.8.4 Strategic Initiatives
7.4.9 Glaxosmithkline Plc.
7.4.9.1 Company Overview
7.4.9.2 Financial Performance
7.4.9.3 Product Benchmarking
7.4.9.4 Strategic Initiatives
7.4.10 Adc Therapeutics Sa
7.4.10.1 Company Overview
7.4.10.2 Financial Performance
7.4.10.3 Product Benchmarking
7.4.10.4 Strategic Initiatives
7.4.11 Synaffix Bv
7.4.11.1 Company Overview
7.4.11.2 Financial Performance
7.4.11.3 Product Benchmarking
7.4.11.4 Strategic Initiatives
Chapter 8. Kol Recommendations/ Conclusion
List of Tables
Table 1 List of abbreviation
TABLE 2 List of secondary sources
TABLE 3 Global antibody-drug conjugates market estimates and forecasts, by region, 2018 - 2030 (USD Million)
TABLE 4 Global antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 5 Global antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 6 Global antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 7 Global antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 8 North America antibody-drug conjugates market estimates and forecasts, by country, 2018 - 2030 (USD Million)
TABLE 9 North America antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 10 North America antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 11 North America antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 12 North America antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 13 U.S. antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 14 U.S. antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 15 U.S. antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 16 U.S. antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 17 Canada antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 18 Canada antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 19 Canada antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 20 Canada antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 21 Europe antibody-drug conjugates market estimates and forecasts, by country, 2018 - 2030 (USD Million)
TABLE 22 Europe antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 23 Europe antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 24 Europe antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 25 Europe antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 26 U.K. antibody-drug conjugates market estimates and forecasts, by application, 2017 - 62028 (USD Million)
TABLE 27 UK antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 28 UK antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 29 UK antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 30 Germany antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 31 Germany antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 32 Germany antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 33 Germany antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 34 France antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 35 France antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 36 France antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 37 France antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 38 Italy antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 39 Italy antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 40 Italy antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 41 Italy antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 42 Spain antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 43 Spain antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 44 Spain antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 45 Spain antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 46 Denmark antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 47 Denmark antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 48 Denmark antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 49 Denmark antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 50 Sweden antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 51 Sweden antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 52 Sweden antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 53 Sweden antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 54 Norway antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 55 Norway antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 56 Norway antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 57 Norway antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 58 Asia Pacific antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 59 Asia Pacific antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 60 Asia Pacific antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 61 Asia Pacific antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 62 Japan antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 63 Japan antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 64 Japan antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 65 Japan antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 66 China antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 67 China antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 68 China antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 69 China antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 70 India antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 71 India antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 72 India antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 73 India antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 74 Australia antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 75 Australia antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 76 Australia antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 77 Australia antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 78 South Korea antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 79 South Korea antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 80 South Korea antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 81 South Korea antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 82 Thailand antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 83 Thailand antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 84 Thailand antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 85 Thailand antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 86 Latin America antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 87 Latin America antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 88 Latin America antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 89 Latin America antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 90 Brazil antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 91 Brazil antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 92 Brazil antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 93 Brazil antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 94 Mexico antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 95 Mexico antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 96 Mexico antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 97 Mexico antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 98 Argentina antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 99 Argentina antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 100 Argentina antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 101 Argentina antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 102 MEA antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 103 MEA antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 104 MEA antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 105 MEA antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 106 South Africa antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 107 South Africa antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 108 South Africa antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 109 South Africa antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 110 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 111 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 112 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 113 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 114 UAE antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 115 UAE antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 116 UAE antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 117 UAE antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 118 Kuwait antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 119 Kuwait antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 120 Kuwait antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 121 Kuwait antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 122 List of key distributors
TABLE 123 List of key emerging companies/technology disruptors/innovators
List of Figures
Fig. 1 Antibody-drug conjugates market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Antibody-drug conjugates market snapshot
Fig. 10 Antibody-drug conjugates market driver impact
Fig. 11 Global population by age group, 2016, 2022, & 2027
Fig. 12 Global cancer cases projection,2020 - 2030 (Number of new registered cases)
Fig. 13 Antibody-drug conjugates market restraint impact
Fig. 14 Penetration and growth prospect mapping
Fig. 15 SWOT analysis, by factor (political & legal economic and technological)
Fig. 16 Porter’s five forces analysis
Fig. 17 Antibody-drug conjugates market: Application outlook and key takeaways
Fig. 18 Antibody-drug conjugates market: Application movement analysis
Fig. 19 Blood cancer market estimates and forecasts, 2018 - 2030
Fig. 20 Leukemia market estimates and forecasts, 2018 - 2030
Fig. 21 Multiple Myeloma market estimates and forecasts, 2018 - 2030
Fig. 22 Lymphoma market estimates and forecasts, 2018 - 2030
Fig. 23 Breast cancer market estimates and forecasts, 2018 - 2030
Fig. 24 Urothelial cancer market estimates and forecasts, 2018 - 2030
Fig. 25 Others market estimates and forecasts, 2018 - 2030
Fig. 26 Antibody-drug conjugates market: Technology outlook and key takeaways
Fig. 27 Antibody-drug conjugates market: Technology movement analysis
Fig. 28 Cleavable linker market estimates and forecasts, 2018 - 2030
Fig. 29 Non-cleavable linker market estimates and forecasts, 2018 - 2030
Fig. 30 Linkerless market estimates and forecasts, 2018 - 2030
Fig. 31 VC (valine-citrulline) market estimates and forecasts, 2018 - 2030
Fig. 32 Sulfo-SPDB market estimates and forecasts, 2018 - 2030
Fig. 33 VA (valine alanine) market estimates and forecasts, 2018 - 2030
Fig. 34 Hydrazone market estimates and forecasts, 2018 - 2030
Fig. 35 Others market estimates and forecasts, 2018 - 2030
Fig. 36 MMAE market estimates and forecasts, 2018 - 2030
Fig. 37 MMAF market estimates and forecasts, 2018 - 2030
Fig. 38 DM4 market estimates and forecasts, 2018 - 2030
Fig. 39 Camptothecin market estimates and forecasts, 2018 - 2030
Fig. 40 Others market estimates and forecasts, 2018 - 2030
Fig. 41 Antibody-drug conjugates market: Regional outlook and key takeaways
Fig. 42 Antibody-drug conjugates market: Regional movement analysis
Fig. 43 North America SWOT analysis
Fig. 44 North America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 U.S. key country dynamics
Fig. 46 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Canada key country dynamics
Fig. 48 Canada market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Europe SWOT analysis
Fig. 50 Europe market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 UK key country dynamics
Fig. 52 UK market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Germany key country dynamics
Fig. 54 Germany market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Italy key country dynamics
Fig. 56 Italy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 57 Spain key country dynamics
Fig. 58 Spain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 59 Denmark key country dynamics
Fig. 60 Denmark market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 61 Sweden key country dynamics
Fig. 62 Sweden market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 63 Norway key country dynamics
Fig. 64 Norway market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 65 France key country dynamics
Fig. 66 France market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 67 Asia Pacific SWOT analysis
Fig. 68 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 69 Japan key country dynamics
Fig. 70 Japan market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 71 China key country dynamics
Fig. 72 China market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 73 India key country dynamics
Fig. 74 India market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 75 Australia key country dynamics
Fig. 76 Australia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 77 South Korea key country dynamics
Fig. 78 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 79 Thailand key country dynamics
Fig. 80 Thailand market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 81 Latin America SWOT analysis
Fig. 82 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 83 Brazil key country dynamics
Fig. 84 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 85 Mexico key country dynamics
Fig. 86 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 87 Argentina key country dynamics
Fig. 88 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 89 Middle East & Africa SWOT analysis
Fig. 90 Middle East and Africa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 91 South Africa key country dynamics
Fig. 92 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 93 Saudi Arabia key country dynamics
Fig. 94 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 95 UAE key country dynamics
Fig. 96 UAE market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 97 Kuwait key country dynamics
Fig. 98 Kuwait market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 99 Company market share analysis
Fig. 100 Company market position analysis (Revenue US$ mn)
Fig. 101 Company market position analysis (Profit Margin)
Fig. 102 Competitive dashboard analysis
Fig. 103 Regional Network Map

Companies Mentioned

  • Takeda Pharmaceutical Company Limited
  • F.Hoffmann-La Roche Ltd.
  • Pfizer, Inc.
  • Astrazeneca
  • Gilead Sciences, Inc.
  • Astellas Pharma Inc.
  • Seagen, Inc.
  • Daiichi Sankyo Company, Limited
  • Glaxosmithkline Plc.
  • Adc Therapeutics Sa
  • Synaffix Bv

Methodology

Loading
LOADING...

Related Topics

Related Reports

ADC Technology Market: Focus on ADC Linker and ADC Conjugation Technologies (2nd Edition) - Distribution by Generation of ADC Technology, Type of Conjugation, Type of Linker and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035 - Product Image

ADC Technology Market: Focus on ADC Linker and ADC Conjugation Technologies (2nd Edition) - Distribution by Generation of ADC Technology, Type of Conjugation, Type of Linker and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

  • Report
  • 407 Pages
  • Global
From
Global Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type (Calicheamicin, MMAE), Target (HER2, CD30, CD22), Disease, and Region - Forecast to 2028 - Product Image

Global Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type (Calicheamicin, MMAE), Target (HER2, CD30, CD22), Disease, and Region - Forecast to 2028

  • Report
  • 273 Pages
  • Global
From
Antibody Drug Conjugate Market (7th Edition): Distribution by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens And Key Geographical Regions (North America, Europe, and Asia-Pacific): Industry Trends and Global Forecasts, 2023-2035 - Product Image

Antibody Drug Conjugate Market (7th Edition): Distribution by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens And Key Geographical Regions (North America, Europe, and Asia-Pacific): Industry Trends and Global Forecasts, 2023-2035

  • Report
  • 716 Pages
  • Global
From
Global Antibody Drug Conjugate Market by Mechanism of Action (CD30 Antibodies, ErbB2 Antibodies), Drugs (Adcetris, Blenrep, Enhertu), Technology, Indication, End User - Forecast 2023-2030 - Product Image

Global Antibody Drug Conjugate Market by Mechanism of Action (CD30 Antibodies, ErbB2 Antibodies), Drugs (Adcetris, Blenrep, Enhertu), Technology, Indication, End User - Forecast 2023-2030

  • Report
  • 181 Pages
  • Global
From
Global Antibody Drug Conjugates Contract Manufacturing Market by Linker (Cleavable, Non-cleavable), Condition (Breast Cancer, Lymphoma, Myeloma), End Use - Forecast 2024-2030 - Product Image

Global Antibody Drug Conjugates Contract Manufacturing Market by Linker (Cleavable, Non-cleavable), Condition (Breast Cancer, Lymphoma, Myeloma), End Use - Forecast 2024-2030

  • Report
  • 193 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.